Article: Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation
File Download
(May Require Subscription)
- No File Attached
(May Require Subscription)
- Publisher Website: 10.1053/j.gastro.2011.06.083
- Scopus: eid_2-s2.0-80053583302
- PMID: 21762659
- Find via
Supplementary
-
Citations:
-
Appears in Collections:
| Title | Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation | ||||
|---|---|---|---|---|---|
| Authors | Fung, JYY1 Cheung, C1 Chan, SC1 Yuen, MF1 Chok, KSH1 Sharr, W1 Dai, WC Chan, ACY1 Cheung, TT Tsang, S1 Lam, B1 Lai, CL1 Lo, CM1 | ||||
| Issue Date | 2011 | ||||
| Publisher | WB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro | ||||
| Citation | Gastroenterology, 2011, v. 141 n. 4, p. 1212-1219 [How to Cite?] DOI: http://dx.doi.org/10.1053/j.gastro.2011.06.083 | ||||
| Abstract | BACKGROUND and AIMS: We investigated the efficacy of entecavir, a cyclopentyl guanosine nucleoside analogue, as monoprophylaxis in patients with chronic hepatitis B who received a liver transplant. METHODS: We studied data from 80 consecutive patients who received a liver transplant (47 from living donors and 33 from deceased donors) for hepatitis B-related disease and entecavir monotherapy as prophylaxis. None of the patients received hepatitis B immunoglobulin. Indications for transplant included decompensation from cirrhosis (27.5%), acute-on-chronic hepatitis B (47.5%), and hepatocellular carcinoma (25%). The median follow-up time was 26 months (range, 5-40 months). Before transplant, 33 patients were not on antiviral therapy and 47 were on oral therapy (18 had received less than 3 months of treatment). RESULTS: At the time of transplant, the median log HBV DNA level was 3.5 copies/mL (range, 1.54-8.81); 21 patients (26%) had undetectable levels of HBV DNA. The cumulative rate of hepatitis B surface antigen (HBsAg) loss was 86% and 91% after 1 and 2 years, respectively. Ten patients had reappearance of HBsAg. Eighteen patients (22.5%) were HBsAg positive at the time of their last examination; 17 of these had undetectable levels of HBV DNA, and the remaining patient had a low level of HBV DNA (217 copies/mL). There was no evidence of mutations at sites that confer resistance to entecavir among patients who were HBsAg positive. CONCLUSIONS: Although only 26% of patients had complete viral suppression at the time of transplant, 91% lost HBsAg, with 98.8% achieving undetectable levels of HBV DNA. A hepatitis B immunoglobulin-free regimen of entecavir monotherapy is effective after liver transplantation for chronic hepatitis B. | ||||
| ISSN | 0016-5085 2011 Impact Factor: 11.675 2011 SCImago Journal Rankings: 1.055 | ||||
| DOI | http://dx.doi.org/10.1053/j.gastro.2011.06.083 | ||||
| ISI Accession Number ID | WOS:000295593700028
Funding Information: The authors disclose the following: Man-Fung Yuen has received speakers' bureau and research grants from Bristol-Myers Squibb. Ching-Lung Lai and James Fung have been invited speakers for Bristol-Myers Squibb. The remaining authors disclose no conflicts. | ||||
| References | References in Scopus |
| dc.contributor.author | Fung, JYY | ||||
|---|---|---|---|---|---|
| dc.contributor.author | Cheung, C | ||||
| dc.contributor.author | Chan, SC | ||||
| dc.contributor.author | Yuen, MF | ||||
| dc.contributor.author | Chok, KSH | ||||
| dc.contributor.author | Sharr, W | ||||
| dc.contributor.author | Dai, WC | ||||
| dc.contributor.author | Chan, ACY | ||||
| dc.contributor.author | Cheung, TT | ||||
| dc.contributor.author | Tsang, S | ||||
| dc.contributor.author | Lam, B | ||||
| dc.contributor.author | Lai, CL | ||||
| dc.contributor.author | Lo, CM | ||||
| dc.date.accessioned | 2011-08-26T14:24:07Z | ||||
| dc.date.available | 2011-08-26T14:24:07Z | ||||
| dc.date.issued | 2011 | ||||
| dc.description.abstract | BACKGROUND and AIMS: We investigated the efficacy of entecavir, a cyclopentyl guanosine nucleoside analogue, as monoprophylaxis in patients with chronic hepatitis B who received a liver transplant. METHODS: We studied data from 80 consecutive patients who received a liver transplant (47 from living donors and 33 from deceased donors) for hepatitis B-related disease and entecavir monotherapy as prophylaxis. None of the patients received hepatitis B immunoglobulin. Indications for transplant included decompensation from cirrhosis (27.5%), acute-on-chronic hepatitis B (47.5%), and hepatocellular carcinoma (25%). The median follow-up time was 26 months (range, 5-40 months). Before transplant, 33 patients were not on antiviral therapy and 47 were on oral therapy (18 had received less than 3 months of treatment). RESULTS: At the time of transplant, the median log HBV DNA level was 3.5 copies/mL (range, 1.54-8.81); 21 patients (26%) had undetectable levels of HBV DNA. The cumulative rate of hepatitis B surface antigen (HBsAg) loss was 86% and 91% after 1 and 2 years, respectively. Ten patients had reappearance of HBsAg. Eighteen patients (22.5%) were HBsAg positive at the time of their last examination; 17 of these had undetectable levels of HBV DNA, and the remaining patient had a low level of HBV DNA (217 copies/mL). There was no evidence of mutations at sites that confer resistance to entecavir among patients who were HBsAg positive. CONCLUSIONS: Although only 26% of patients had complete viral suppression at the time of transplant, 91% lost HBsAg, with 98.8% achieving undetectable levels of HBV DNA. A hepatitis B immunoglobulin-free regimen of entecavir monotherapy is effective after liver transplantation for chronic hepatitis B. | ||||
| dc.description.nature | Link_to_subscribed_fulltext | ||||
| dc.identifier.citation | Gastroenterology, 2011, v. 141 n. 4, p. 1212-1219 [How to Cite?] DOI: http://dx.doi.org/10.1053/j.gastro.2011.06.083 | ||||
| dc.identifier.doi | http://dx.doi.org/10.1053/j.gastro.2011.06.083 | ||||
| dc.identifier.epage | 1219 | ||||
| dc.identifier.hkuros | 192486 | ||||
| dc.identifier.hkuros | 189826 | ||||
| dc.identifier.isi | WOS:000295593700028
Funding Information: The authors disclose the following: Man-Fung Yuen has received speakers' bureau and research grants from Bristol-Myers Squibb. Ching-Lung Lai and James Fung have been invited speakers for Bristol-Myers Squibb. The remaining authors disclose no conflicts. | ||||
| dc.identifier.issn | 0016-5085 2011 Impact Factor: 11.675 2011 SCImago Journal Rankings: 1.055 | ||||
| dc.identifier.issue | 4 | ||||
| dc.identifier.openurl | | ||||
| dc.identifier.pmid | 21762659 | ||||
| dc.identifier.scopus | eid_2-s2.0-80053583302 | ||||
| dc.identifier.spage | 1212 | ||||
| dc.identifier.uri | http://hdl.handle.net/10722/137375 | ||||
| dc.identifier.volume | 141 | ||||
| dc.language | eng | ||||
| dc.publisher | WB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro | ||||
| dc.publisher.place | United States | ||||
| dc.relation.ispartof | Gastroenterology | ||||
| dc.relation.references | References in Scopus | ||||
| dc.subject.mesh | Antiviral Agents - adverse effects - therapeutic use | ||||
| dc.subject.mesh | Carcinoma, Hepatocellular - surgery - virology | ||||
| dc.subject.mesh | Guanine - adverse effects - analogs and derivatives - therapeutic use | ||||
| dc.subject.mesh | Hepatitis B, Chronic - complications - diagnosis - drug therapy - surgery | ||||
| dc.subject.mesh | Liver Cirrhosis - surgery - virology | ||||
| dc.title | Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation | ||||
| dc.type | Article |
Author Affiliations
- The University of Hong Kong